A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
50 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who has a low bone mineral density at hip or vertebral
Patients who has an osteoporotic fracture at hip or vertebra
Hypersensitivity either to the active substance or to any of the excipients or to any biphosphonates.
Known metabolic bone disease excluding osteoporosis.
Serious systemic disorder treated with drugs interfering with bone metabolism.
Significant liver or renal failure
Pathologic fracture in the examined body area or elsewhere.
Previous anti-osteoporotic treatment within 12 months or less prior to the recruitment.
Patients with hypocalcaemia
Other protocol-defined inclusion/exclusion criteria may apply